ASCO 2024 News


Intracranial Antitumor Activity Observed With Dato-DXd In Previously Treated Patients With Advanced Or Metastatic NSCLC, Study Finds

OncLive (6/3, Kahl) reports, “According to findings from a post-hoc analysis of the phase 2 TROPION-Lung05 trial (NCT04484142), intracranial antitumor activity was observed with datopotamab deruxtecan (Dato-DXd) in previously treated patients with advanced or metastatic non-small cell lung cancer (NSCLC), including those with brain metastases at baseline.” In the study, “53 patients with baseline brain metastases demonstrated an overall response rate (ORR) of 28% (95% CI, 17%-42%), including no complete responses (CRs), 28% with partial responses (PRs), 40% with stable disease (SD), and 19% with progressive disease (PD).” These results “were presented during the 2024 ASCO Annual Meeting.”

Neoadjuvant Nivolumab Combined With Chemo Demonstrated Durable EFS, Trend Toward Improved OS Compared To Chemo Alone In Patients With Resectable NSCLC, Trial Finds

OncLive (6/3, Rosa) reports, “Neoadjuvant nivolumab (Opdivo) paired with chemotherapy showcased durable event-free survival (EFS) benefit and a trend toward improved overall survival (OS) vs chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC), according to data from the 4-year update of the phase 3 CheckMate 816 study.” Study results “showed that the median EFS with nivolumab plus chemotherapy (n = 179) was 43.8 months (95% CI, 30.6-not reached [NR]) vs 18.4 months (95% CI, 14.0-26.7) with chemotherapy alone (n = 179), with a hazard ratio of 0.66 (95% CI, 0.49-0.90).” The findings were presented at the 2024 ASCO Annual Meeting,

Linvoseltamab Resulted In Similar, Better Outcomes Compared To Teclistamab In Patients With Triple-Class Exposed R/R Multiple Myeloma, Study Finds

Targeted Oncology (6/3, Benyon) reports, “Linvoseltamab tended to lead similar or better outcomes as teclistamab (Tecvayli) in patients with relapsed or refractory multiple myeloma that have been exposed [to] 3 or more prior therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody, according to a systemic literature review presented at the 2024 ASCO Annual Meeting.” In the study, “rates of complete response (45% vs 32%; OR = 1.74; 95% CI, 1.17-2.59), progression-free survival (not reached [NR] vs 10.10 months; OR = 0.52; 95% CI, 0.33-0.83), and time to next therapy (NR vs NR; OR = 0.49; 95% CI, 0.29-0.84) continued to be significantly higher with linvoseltamab compared with teclistamab.”

Subcutaneous Envafolimab Plus Oral Lenvatinib Demonstrates Durable ORRs, Manageable Safety In Certain Patients With Advanced Endometrial Cancer, Study Finds

Targeted Oncology (6/3, Cohn-Emery) reports, “Envafolimab (KN035) given subcutaneously plus oral lenvatinib (Lenvima) demonstrated durable overall response rates (ORRs) and a manageable safety profile in patients with advanced endometrial cancer who were not microsatellite instability-high (MSI) or mismatch repair deficient (dMMR) after prior lines of therapy, according to data presented at the 2024 ASCO Annual Meeting.” In the study, “there was a confirmed ORR of 40.0% (95% CI, 21.1%-61.3%) in the primary end point analysis of 25 patients at the data cutoff July 12, 2023. The best overall response was partial response in 10 patients (40.0%), stable disease in 11 (44.0%), and progressive disease in 3 (12.0%).”

Adjuvant Atezolizumab Provides DFS Benefit Compared To BSC For Select Patients With Resected Stage II To IIIA NSCLC, Study Finds

OncLive (6/3, Pelosci) reports, “Treatment with adjuvant atezolizumab (Tecentriq) continued to produce a disease-free survival (DFS) benefit vs best supportive care (BSC), leading to superior overall survival (OS) outcomes for select patients with resected stage II to IIIA non-small cell lung cancer (NSCLC), according to 5-year follow-up data from the phase 3 IMpower010 trial (NCT02486718) presented during the 2024 ASCO Annual Meeting.” In the study, “the rate of DFS events in the atezolizumab arm was 47.1% vs 52.2% in the BSC arm for patients in the intent-to-treat (ITT) population. Additionally, DFS events in the stage II to IIIA population affected 49.5% and 54.5%, respectively.”

Adagrasib Improves Responses, PFS In Patients With Advanced NSCLC Harboring KRAS G12C Mutation, Research Finds

Oncology Nursing News (6/3, Kahl) reports, “Adagrasib (Krazati) for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) induced a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared with docetaxel, in patients who had previously received a platinum-based chemotherapy, concurrently or sequentially with anti-PD-(L)1 therapy.” Additionally, “according to the primary analysis of the phase 3 KRYSTAL-12 trial…presented at the 2024 ASCO Annual Meeting, overall response rate…appeared significantly higher, with a more than doubled intracranial response rate among patients treated with adagrasib, compared with standard-of-care chemotherapy.”

Anthracycline Plus A Taxane And Cyclophosphamide Reduced Risk For Recurrence In Patients With MP High-2–Risk, HR+/HER2– Early Breast Cancer, Trial Finds

Oncology Nursing News (6/3, Scott) reports, “Treatment with anthracycline plus a taxane and cyclophosphamide reduced the risk for recurrence at 3 years in MammaPrint (MP) high-2–risk, BluePrint Luminal B, hormone receptor (HR)–positive, HER2-negative early breast cancer, according to data from the prospective, observational, nonrandomized FLEX registry trial.” The “findings showed that patients with Luminal MP high-1–risk disease had comparable 3-year recurrence-free survival (RFS) rates when treated with a taxane and cyclophosphamide…at 97.1%…and with anthracycline plus a taxane and cyclophosphamide…at 95.3%.” But, “patients with Luminal MP high-2–risk disease had a worse 3-year RFS rate when treated with the 2-drug regimen…at 86.4%…compared with the anthracycline regimen…at 97.7%.” The findings were presented at the 2024 ASCO Annual Meeting.

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit Vs Sunitinib Regardless Of Biomarker Subtypes In Patients With ccRCC, Trial Finds

OncLive (6/3, Hollasch) reports, “Regardless of patient biomarker subtype, lenvatinib (Lenvima) plus pembrolizumab (Keytruda) produced greater clinical benefit vs sunitinib (Sutent) in advanced clear cell renal cell carcinoma (RCC) when the primary end point of progression-free survival (PFS) and secondary end point of objective response rate (ORR) of the phase 3 CLEAR trial…were examined.” The “findings from a biomarker analysis of CLEAR presented at the 2024 ASCO Annual Meeting revealed that PFS consistently favored lenvatinib plus pembrolizumab vs sunitinib regardless of mutation status of RCC driver genes.” Meanwhile, “a PFS benefit was observed in patients with mutated VHL…PBRM1…SETD2…BAP1…and KDM5C…which were the most frequently mutated genes.”